Perspective Therapeutics, INC Form 4 insider transactions

Perspective Therapeutics CEO, Johan M. Spoor, purchased shares of the company's common stock in multiple transactions on November 25, 2024.

Mark John Austin, VP of Finance at Perspective Therapeutics, acquired 34,500 stock options on July 17, 2024.

Director Robert F. Williamson III acquired 23,000 stock options in Perspective Therapeutics, Inc. on June 20, 2024.

Frank Morich, a director of Perspective Therapeutics, Inc., acquired 23,000 stock options on June 20, 2024.

Lori A. Woods, a director of Perspective Therapeutics, Inc., acquired stock options for 23,000 shares on June 20, 2024.

Heidi Henson, a director at Perspective Therapeutics, acquired 23,000 stock options on June 20, 2024, exercisable at $10.65 per share.

Johan M. Spoor, CEO of Perspective Therapeutics, Inc., reports the acquisition of 500,000 stock options on June 20, 2024.

Markus Puhlmann, Chief Medical Officer of Perspective Therapeutics, Inc., reports the acquisition of 150,000 stock options.

Jonathan Hunt, CFO of Perspective Therapeutics, Inc., reports the acquisition of 100,000 stock options on June 20, 2024.

Jonathan Hunt, CFO of Perspective Therapeutics, Inc., purchased 1,800 shares of common stock at a price of $9.815 per share on June 17, 2024.

Director Lori Woods reports acquiring and disposing of Perspective Therapeutics (CATX) common stock through direct and indirect ownership.

Perspective Therapeutics CEO Johan Spoor purchased 100,000 shares of common stock at a weighted average price of $1.1743 on June 13, 2024.

Lori A. Woods, a director of Perspective Therapeutics, Inc., amended a previous SEC filing to clarify the nature of her beneficial ownership of company stock.

Director Lori A. Woods reports acquisition of 34,246 shares of Perspective Therapeutics (CATX) at $1.4598 per share.

Jonathan Hunt, CFO of Perspective Therapeutics, recently purchased shares of the company's common stock, increasing his beneficial ownership.

Director Robert F. Williamson III recently purchased 55,000 shares of Perspective Therapeutics, Inc. (CATX) at $1.38 per share, increasing his direct holdings.

Robert F. Williamson III, a director at Perspective Therapeutics, Inc., recently acquired additional shares of common stock through a series of transactions.

Mark John Austin, VP of Finance/Principal Financial & Accounting Officer at Perspective Therapeutics, exercised stock options to acquire 30,000 shares of common stock at $0.36 per share.

Lantheus Alpha Therapy, a subsidiary of Lantheus Holdings, increases its stake in Perspective Therapeutics through a recent transaction.